Skip to main content

Table 3 Adverse events regarding CTCAE-3 in the XELIRI and FOLFIRI arms, data are shown as n (%)

From: Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

  XELIRI FOLFIRI  
  N = 41 n = 46 p
Hand-foot syndrome    
   Grade 1 4 (10%) 0 0.18
   Grade 2 2 (5%) 0 0.10
   Grade 3 0 0 -
Diarrhoea    
   Grade 1 1 (2%) 4 (8%) 0.18
   Grade 2 4 (10%) 7 (15%) 0.37
   Grade 3 1 (2%) 2 (4%) 0.56
   Grade 4 2 (5%) 1 (2%) 0.56
Nausea    
   Grade 1 3 (7%) 8 (17%) 0.13
   Grade 2 6 (15%) 1 (2%) 0.06
   Grade 3 0 0 -
   Grade 4 0 0 -
Fatigue    
   Grade 1 3 (7%) 4 (9%) 0.70
   Grade 2 1 (2%) 2 (4%) 0.56
   Grade 3 0 0 -
   Grade 4 0 0 -
Neutropenia    
   Grade 1 3 (7%) 2 (4%) 0.65
   Grade 2 2 (5%) 12 (26%) 0.008
   Grade 3 1 (2%) 5 (11%) 0.10
   Grade 4 1 (2%) 1 (2%) 1.0
Thrombopenia of any grade 0 0 -
Ischemic stroke 0 1 (2%) -
Acute coronary syndrome 1 (2%) 2 (4%) 0.56
Death* 0 0 -
  1. * Patients who died within 30 days after the last cycle of chemotherapy or liver surgery